Upgrades - UBS upgraded UiPath (PATH) to Neutral from Sell with a price target of $17, up from $10, citing that near-term GenAI risk fears appear "overdone" [2] - Needham upgraded TransMedics (TMDX) to Buy from Hold with a price target of $148, indicating that U.S. sales are likely to beat consensus in Q3 according to their transplant tracker [2] - Deutsche Bank upgraded CME Group (CME) to Buy from Hold with a price target of $300, up from $266, believing that organic growth initiatives will drive earnings growth into the high single digits by 2026 [3] - Roth Capital upgraded Core Scientific (CORZ) to Buy from Neutral with a price target of $23.50, up from $17, assuming that the takeover by CoreWeave (CRWV) will not go through [4] - JPMorgan upgraded LendingClub (LC) to Overweight from Neutral with a price target of $22, up from $17, noting that the company has "more ways than ever" to grow originations and profits [5] Downgrades - Mizuho downgraded Enphase Energy (ENPH) to Neutral from Outperform with a price target of $37, down from $50, due to reduced residential solar demand and lower market share [6] - Mizuho downgraded Hologic (HOLX) to Neutral from Outperform with a price target of $78 after the company agreed to be acquired in a transaction valued at up to $79 per share [6] - Wells Fargo downgraded Tegna (TGNA) to Equal Weight from Overweight with an unchanged price target of $22, citing the pending Nexstar (NXST) acquisition [6] - H.C. Wainwright downgraded Avadel Pharmaceuticals (AVDL) to Neutral from Buy with a price target of $20, down from $36, following a definitive agreement to be acquired by Alkermes (ALKS) [6] - Citi downgraded Arcturus Therapeutics (ARCT) to Neutral from Buy with a price target of $12, down from $49, due to disappointing results from the ARCT-032 Phase 2 trial [6]

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stock was trading lower on Wednesday after the company shared interim results from its ongoing Phase 2 trial of ARCT-032, an investigational inhaled mRNA therapy for cystic fibrosis.In the second cohort of the study, six Class I CF adults received inhaled 10 mg doses of ARCT-032 daily over 28 days. The treatment was generally safe and well-tolerated.Treatment-related AEs identified in the single-dose Phase 1 study were also observed in some participants for ...

Market Overview - U.S. stocks traded mostly lower, with the Dow Jones index falling more than 100 points, down 0.25% to 46,806.81, NASDAQ down 0.04% to 22,943.73, and S&P 500 down 0.03% to 6,733.39 [1] Company Performance - Netflix Inc shares fell over 8% after reporting third-quarter revenue of $11.51 billion, which was up 17.2% year-over-year but missed the consensus estimate of $11.514 billion. Earnings per share were reported at $5.87, missing the consensus estimate of $6.97 [2] - Beneficient shares surged 155% to $1.2380 following the conversion of preferred shares into common stock by Chairman Thomas O. Hicks and Interim CEO James G. Silk [8] - AiRWA Inc shares increased by 110% to $0.1701 after a previous decline of 19% [8] - Beyond Meat, Inc shares rose 57% to $5.67, driven by short interest, inclusion in the Roundhill Meme Stock ETF, and a distribution partnership with Walmart [8] - Arcturus Therapeutics Holdings Inc shares dropped 57% to $9.95 after announcing interim results from a Phase 2 clinical trial [8] - Alector, Inc shares fell 52% to $1.5301 after announcing the discontinuation of an open-label extension for Latozinemab and a workforce reduction of about 49% [8] - Obook Holdings Inc shares decreased by 41% to $11.46, likely due to post-IPO volatility [8] Economic Indicators - The volume of mortgage applications declined by 0.3% from the previous week during the week ending October 17 [9]

Core Insights - Arcturus Therapeutics' stock plummeted over 55% following mixed results from a monthlong study of its experimental cystic fibrosis treatment using mRNA technology [1][3] - The study indicated no significant improvement in forced expiratory volume (FEV), a critical measure for cystic fibrosis patients, although some patients showed reduced mucous burden [2][3] - Analysts have differing opinions on the results, with one suggesting potential clinical benefits at high doses, while another described the data as underwhelming [3] Company Performance - Arcturus Therapeutics' stock fell to $10.27 after previously rising 188% from a low of $8.04 in April [3] - The company had a strong IBD Digital Relative Strength Rating of 92, placing it in the top 8% of all stocks based on 12-month performance [3] Analyst Commentary - William Blair analyst Myles Minter noted potential for clinical benefit at high doses [3] - Leerink Partners analyst Lili Nsongo characterized the data as underwhelming, reflecting a cautious outlook on the treatment's efficacy [3]

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) tumbled by more than 56% on Wednesday after the company reported interim results from its Phase 2 study of ARCT-032, an inhaled mRNA therap... ...

Company Overview - Arcturus Therapeutics (ARCT) shares increased by 7.7% to $23.16 in the last trading session, with a higher-than-average trading volume [1] - The stock has gained 2.3% over the past four weeks [1] Pipeline and Development - The positive investor sentiment is linked to ARCT's pipeline, which includes two mRNA therapeutic candidates: ARCT-810 for ornithine transcarbamylase deficiency and ARCT-032 for cystic fibrosis, both in mid-stage development [2] - Arcturus has partnered with CSL Seqirus to develop Kostaive, the world's first sa-mRNA COVID-19 vaccine, which is approved in Japan and the EU [2] Financial Expectations - The company is expected to report a quarterly loss of $1.09 per share, reflecting a year-over-year decline of 319.2% [3] - Projected revenues for the upcoming quarter are $16.67 million, down 60% from the same quarter last year [3] Earnings Estimates and Stock Performance - The consensus EPS estimate for Arcturus has remained unchanged over the last 30 days, indicating a lack of upward revisions [4] - The stock's price typically does not continue to rise without trends in earnings estimate revisions, suggesting the need for monitoring future performance [4] - Arcturus currently holds a Zacks Rank of 1 (Strong Buy) [4] Industry Comparison - In the same industry, Septerna, Inc. (SEPN) saw a 5% decrease in its stock price, closing at $21.31, but has returned 40.3% over the past month [4] - Septerna's consensus EPS estimate has remained unchanged at $0.19, representing a 102.3% increase from the previous year, and it holds a Zacks Rank of 3 (Hold) [5]

Core Insights - U.S. stock markets are experiencing a continued upward trend in 2025, following a strong rally over the past two years, with expectations for the Fed to lower benchmark lending rates due to a weak labor market [1][2] Market Sentiment - Recent U.S. government shutdown and delays in key economic data releases may dampen investor enthusiasm, alongside trade conflicts with China affecting market sentiment [2] - Despite these challenges, some stocks have shown price strength, particularly those on a recent bull run, indicating potential for continued momentum [2][3] Stock Screening - Four stocks identified with recent price strength include Flux Power Holdings Inc. (FLUX), Aura Minerals Inc. (AUGO), Arcturus Therapeutics Holdings Inc. (ARCT), and Sterling Infrastructure Inc. (STRL) [3][8] - The screening criteria for these stocks include: - Percentage Change in Price (4 Weeks) greater than zero - Percentage Change in Price (12 Weeks) greater than 10 - Zacks Rank 1 (Strong Buy) - Average Broker Rating of 1 - Current Price greater than $5 - Current Price/52-Week High-Low Range more than 85% [5][6][7] Individual Stock Performance - **Flux Power Holdings Inc. (FLUX)**: Stock price increased by 92.1% in four weeks, with an expected earnings growth rate of 82.4% for the current year, and earnings estimates rising by 40% over the past 60 days [8][9] - **Aura Minerals Inc. (AUGO)**: Stock price climbed 9.3% in four weeks, with an expected earnings growth rate exceeding 100% for the current year, and earnings estimates improving by 2.5% over the past week [10][11] - **Arcturus Therapeutics Holdings Inc. (ARCT)**: Stock price advanced 2.3% in four weeks, with an expected earnings growth rate of -10% for the current year, and earnings estimates improving by 11.5% over the past 90 days [11][12] - **Sterling Infrastructure Inc. (STRL)**: Stock price gained 0.4% in four weeks, with an expected earnings growth rate of 56.9% for the current year, and earnings estimates improving by 9.7% over the past 60 days [13][15]

Core Viewpoint - The article emphasizes the importance of identifying and sustaining stock price trends for successful short-term investing, highlighting the need for strong fundamentals and positive earnings revisions to maintain momentum [1][2]. Group 1: Stock Performance - Arcturus Therapeutics (ARCT) has shown a significant price increase of 46.3% over the past 12 weeks, indicating strong investor interest [4]. - The stock has also experienced a 17.5% price increase in the last four weeks, suggesting that the upward trend is still intact [5]. - ARCT is currently trading at 84.9% of its 52-week high-low range, indicating a potential breakout opportunity [5]. Group 2: Fundamental Strength - ARCT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The article suggests that investors can utilize the "Recent Price Strength" screen to identify stocks like ARCT that are on an upward trend supported by strong fundamentals [3][8]. - It also mentions the availability of over 45 Zacks Premium Screens tailored to different investing styles, which can help in finding potential winning stocks [8].

Group 1 - Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock has experienced a rise of slightly above 20% this month, resulting in double-digit gains [1] - The company previously thrived during the COVID boom due to large upfront payments and government contracts, which drove peak revenues and visibility [1] Group 2 - The current performance of Arcturus Therapeutics indicates a potential recovery or growth phase following the pandemic-related surge [1]

Company Overview - Arcturus Therapeutics (ARCT) shares increased by 8.7% to close at $19.62, with trading volume significantly higher than usual, contrasting with a 4% gain over the past four weeks [1][2] Pipeline and Product Development - The recent stock uptick is driven by positive investor sentiment regarding ARCT's pipeline, which includes two mRNA therapeutic candidates: ARCT-810 for ornithine transcarbamylase deficiency and ARCT-032 for cystic fibrosis, both in mid-stage development [2] - Arcturus has partnered with CSL Seqirus to develop Kostaive, the world's first sa-mRNA COVID-19 vaccine, which is currently approved in Japan and the EU [2] Financial Performance Expectations - The company is expected to report a quarterly loss of $1.09 per share, reflecting a year-over-year decline of 319.2%, with revenues projected at $16.67 million, down 60% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has been revised 13% lower over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4] Industry Context - Arcturus Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry, where Anika Therapeutics (ANIK) also operates, having closed 3.2% higher at $8.94, with a 3.5% return over the past month [4] - Anika's consensus EPS estimate for its upcoming report remains unchanged at $0.02, representing a year-over-year increase of 108%, and it holds a Zacks Rank of 2 (Buy) [5]